<DOC>
	<DOCNO>NCT00333567</DOCNO>
	<brief_summary>This study design investigate efficacy safety single daily dose 400 mg lumiracoxib give pre-emptively versus post-operatively term efficacy reduce pain associate ambulatory arthroscopic knee surgery</brief_summary>
	<brief_title>Efficacy Safety Lumiracoxib 400 mg Arthroscopic Knee Surgery</brief_title>
	<detailed_description />
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Patients need schedule minor ambulatory arthroscopic knee surgery . Patients surgical medical condition could place patient high risk his/her participation study , likely prevent patient comply requirement study complete trial period . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>arthroscopic knee surgery</keyword>
	<keyword>cyclooxygenase-2 inhibitor</keyword>
	<keyword>lumiracoxib</keyword>
	<keyword>COX189</keyword>
	<keyword>Ambulatory arthroscopic knee surgery</keyword>
</DOC>